Related Experiment Videos

[Clarithromycin in pediatric age. Personal experience]

A Paffetti1, C Mastropietro, P Mannozzi

  • 1II Divisione Malattie Infettive, Policlinico Umberto I, Roma.

Minerva Pediatrica
|April 1, 1994
PubMed

Insights

Clarithromycin oral suspension effectively treated pediatric respiratory infections in a study of 33 children. The antibiotic demonstrated encouraging therapeutic outcomes with good tolerability and no reported side effects.

Area of Science:

  • Pediatric infectious diseases
  • Respiratory tract infections
  • Antibiotic therapy

Context:

  • Pediatric respiratory infections pose a significant health burden.
  • Clarithromycin is a macrolide antibiotic with broad-spectrum activity.
  • Evaluating the efficacy and safety of oral Clarithromycin suspension in children is crucial.

Purpose:

  • To assess the therapeutic efficacy of oral Clarithromycin suspension.
  • To evaluate the safety and tolerability profile of Clarithromycin in pediatric patients.
  • To determine the optimal dosage regimen for Clarithromycin in treating pediatric respiratory infections.

Summary:

  • A study involved 33 pediatric patients diagnosed with various respiratory tract infections.
  • Patients received oral Clarithromycin suspension at a dosage of 15 mg/kg/day.
  • The treatment yielded highly encouraging therapeutic results, with the drug being well-tolerated.

Impact:

  • Oral Clarithromycin suspension presents a promising treatment option for pediatric respiratory infections.
  • The findings support the use of Clarithromycin in pediatric populations due to its favorable safety profile.
  • This study contributes valuable data on the clinical application of Clarithromycin in pediatric infectious disease management.

Related Concept Videos